IP Library › Granted Patent US 9,777,064
Granted Patent B2
US 9,777,064 · App. 15/070,352 · Granted Oct 3, 2017

Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof

Inventors: Benjamin Wang (Menlo Park, CA); Gusti Zeiner (Pacifica, CA)
Assignee: Chimera Bioengineering, Inc.
C07K16/2887A61K48/0066C12N5/0636A61K2039/505C07K2319/03C07K2319/74C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,777,064
App. No.
15/070,352
Granted
Oct 3, 2017
Kind
B2
Abstract

The present invention relates generally to the field of RNA Control Devices and/or destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) in eukaryotic cells. The present invention also relates to split CARs (Side-CARs) in eukaryotic cells. More specifically, the present invention relates to DEs, RNA Control Devices, and/or side-CARs combined with Chimeric Antigen Receptors to make small molecule actuatable CAR polypeptides. The present invention also relates to DE-CARs, Smart CARs (Smart=small molecule actuatable RNA trigger), Smart-DE-CARs, and/or Side-CARs for use in the treatment of disease.

Claims (13)

1. A nucleic acid comprising: a polynucleotide encoding a RNA control device comprised of a sensor element and a ribozyme element wherein the RNA control device is operably linked to a polynucleotide encoding a chimeric antigen receptor, wherein the chimeric antigen receptor is comprised of an extracellular element, a transmembrane element, and an intracellular element, wherein the ribozyme element acts on an RNA encoding the chimeric antigen receptor and wherein the transmembrane element is between the extracellular element and the intracellular element.

2. The nucleic acid of claim 1 , wherein the polynucleotide encoding the chimeric antigen receptor further comprises a polynucleotide encoding a costimulatory element, wherein the transmembrane element is between the extracellular element and the costimulatory element.

3. The nucleic acid of claim 2 , wherein the costimulatory element is in a domain with the intracellular element.

4. The nucleic acid of claim 2 , wherein the costimulatory element is in a domain separate from the intracellular element.

5. The nucleic acid of claim 1 , further comprising a polynucleotide encoding a hinge element, wherein the hinge element is associated with the transmembrane element.

6. The nucleic acid of claim 1 , further comprising a polynucleotide encoding a hinge element, wherein the hinge element is associated with the extracellular element.

7. A eukaryotic cell comprising a nucleic acid wherein the nucleic acid comprises the polynucleotide of claim 1 .

8. The eukaryotic cell of claim 7 , wherein the eukaryotic cell is a mammalian cell.

9. The eukaryotic cell of claim 8 , wherein the eukaryotic cell is a human cell.

10. The eukaryotic cell of claim 8 , wherein the eukaryotic cell is a murine cell.

11. The eukaryotic cell of claim 7 , wherein the eukaryotic cell is a hematopoietic cell.

12. The eukaryotic cell of claim 11 , wherein the eukaryotic cell is a T-lymphocyte.

13. The eukaryotic cell of claim 11 , wherein the eukaryotic cell is a natural killer cell.

Assignments (2)
SECURITY INTEREST Recorded Mar 31, 2020
From: DRIVER BIOENGINEERING, INC.
To: VENTURE LENDING & LEASING IX, INC.; VENTURE LENDING & LEASING VIII, INC.
Reel/Frame 052276/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2017
From: WANG, BENJAMIN; ZEINER, GUSTI
To: CHIMERA BIOENGINEERING, INC.
Reel/Frame 042534/0332 →
Continuity (5)
Provisional Application 62134143 · Mar 17, 2015
Provisional Application 62152727 · Apr 24, 2015
Provisional Application 62183595 · Jun 23, 2015
Provisional Application 62276449 · Jan 8, 2016
Related Publication 20160272718A1 · Sep 22, 2016